GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Selling and Marketing Expense

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Selling and Marketing Expense : $291 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Tianjin Pharmaceutical Da Ren Tang Group's Selling and Marketing Expense for the three months ended in Mar. 2024 was $77 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $291 Mil.

Tianjin Pharmaceutical Da Ren Tang Group Selling and Marketing Expense Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Selling and Marketing Expense Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 260.78 222.94 244.37 282.47 297.81

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.67 66.37 53.29 94.09 76.84

Tianjin Pharmaceutical Da Ren Tang Group Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $291 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Selling and Marketing Expense
Comparable Companies
SHSE:600380 SZSE:002262 SHSE:600062 SHSE:603707 SZSE:300142 SHSE:600521 SHSE:600535 SHSE:600518 SHSE:600129 SZSE:002773 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
600329:China
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Website
http://www.jydrt.com.cn
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Headlines

No Headlines